REFERENCES
- Garnick M. B. Prostate cancer: screening, diagnosis, and management. Ann. Intern. Med. 1993; 118: 804–818, [PUBMED], [INFOTRIEVE], [CSA]
- Matzkin H., Eber P., Todd B., van der Zwaag R., Soloway M. S. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer 1992; 70: 2302–2309, [PUBMED], [INFOTRIEVE], [CSA]
- Ruckle H. C., Klee G. G., Oesterling J. E. Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy. Mayo Clin. Proc. 1994; 69: 69–79, [INFOTRIEVE], [CSA]
- Amato R. J., Logothetis C. J., Hallinan R., Ro J. Y., Sella A., Dexeus F. H. Chemotherapy for small cell carcinoma of prostatic origin. J. Urol. 1992; 147: 935–937, [INFOTRIEVE], [CSA]
- Ahonen A., Penttila A. Mortality and autopsy rate from urogenital diseases in Finland in 1955–1973. Scand. J. Urol. Nephrol. 1980; 14: 91–99, [INFOTRIEVE], [CSA]
- Roudier M. P., True L. D., Higano C. S., Vesselle H., Ellis W., et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum. Pathol. 2003; 34: 646–653, [INFOTRIEVE], [CROSSREF], [CSA]
- Roudier M. P., Vesselle H., True L. D., Higano C. S., Ott S. M., et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin. Exp. Metastasis 2003; 20: 171–180, [INFOTRIEVE], [CROSSREF], [CSA]